Core Insights - Abbott Laboratories' Diabetes Care business is experiencing significant growth, primarily driven by the FreeStyle Libre continuous glucose monitoring (CGM) platform, which has achieved global leadership in the CGM market for both Type 1 and Type 2 diabetes users [1][2]. Company Developments - Abbott has received FDA approvals for two new over-the-counter CGM systems, Lingo and Libre Rio, expanding its consumer reach and marking a new era in the U.S. market [2][8]. - In Q2 2025, Abbott's CGM sales exceeded $1.90 billion, reflecting a 19.6% organic growth, with U.S. Libre sales increasing nearly 26% [4][8]. - The upcoming launch of Abbott's dual-analyte sensor, which includes ketone monitoring, is expected to enhance its market share, particularly among intensive insulin users [4][8]. Market Trends - The diabetes care devices market is projected to grow significantly, reaching $99.81 billion by 2035, with a compound annual growth rate (CAGR) of 9.6% from 2025 to 2035 [3]. - The increasing aging population, rising obesity rates, and sedentary lifestyles are driving demand in this fast-growing market [3]. Competitive Landscape - Competitors like DexCom and Tandem Diabetes are also expanding their offerings in the CGM space, with DexCom focusing on its G6 and G7 systems and Tandem enhancing its pump portfolio and digital solutions [5][6]. Financial Performance - Year-to-date, Abbott's shares have increased by 19.7%, outperforming the industry growth of 7.9% and the S&P 500's growth of 21.5% [7]. - Abbott currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 4.84X, below the industry average of 5.63X [10].

Core Insights - Garmin has announced partnerships with Brooks, Dexcom, Maurten, Shokz, and Therabody to enhance the Garmin Marathon Series, starting with races in Toledo, Ohio on September 21, 2025 [1][8] Company Contributions - **Brooks**: Provides performance running footwear and apparel, offering participants a branded running shirt and showcasing gear at the expo [3] - **Dexcom**: Offers innovative glucose biosensing technology, including the Dexcom G7 and Stelo, to help runners track glucose levels, with a presence at the expo and finish line festival [4] - **Maurten**: Known for sports nutrition, will supply gels at aid stations to support runners during the event, and will also be present at the expo [5] - **Shokz**: Specializes in open-ear listening technology, will showcase headphones at the expo and provide support at cheer stations during the race [6] - **Therabody**: Focuses on recovery devices to enhance athletic performance, offering exclusive deals and recovery zones throughout the event [7] Event Details - The Garmin Marathon Series will feature events in Toledo, Ohio, and Tucson, Arizona, with four race distances: a full marathon, half marathon, 10K, and 5K, with registration currently open [8]

Core Insights - DexCom reported strong Q2 2025 results with GAAP revenue of $1.16 billion, exceeding analyst estimates of $1.12 billion, and Non-GAAP EPS of $0.48, surpassing the consensus of $0.44, indicating robust performance in the type 2 diabetes market [1][2] Financial Performance - Q2 2025 Non-GAAP EPS was $0.48, up 11.6% from $0.43 in Q2 2024 [2] - GAAP revenue reached $1.16 billion, a 15.2% increase from $1.004 billion in Q2 2024 [2] - Operating income on a GAAP basis was $212.6 million, a 34.6% increase from $158 million in Q2 2024 [2] - Non-GAAP gross margin decreased to 60.1% from 63.5% year-over-year [2][8] - Net income on a Non-GAAP basis was $193 million, reflecting a 10.9% increase from $174 million in Q2 2024 [2] Market and Operational Developments - U.S. sales grew 15% to $841 million, while international revenue rose 16% to $316 million [5] - Sensor and recurring revenue now account for 97% of total sales, up from 94% a year ago, indicating strong demand and patient retention [5] - The company reported record new patient starts, particularly among type 2 diabetes patients, aided by expanded coverage for non-insulin users [6] Product Innovation and Strategy - The FDA approved the Dexcom G7 15 Day CGM System, expected to launch in the second half of 2025, promising longer sensor wear and higher accuracy [7] - The Stelo, an over-the-counter CGM, has gained traction with over 200,000 app downloads and is expected to contribute 2-3% to revenue growth in FY2025 [7] - Strategic partnerships and operational investments are focused on expanding market access and scaling production [4] Future Outlook - Management raised full-year revenue guidance to $4.60–4.63 billion, projecting 14–15% growth [11] - Non-GAAP gross margin is expected to be approximately 62%, with gradual margin improvement anticipated as logistics costs decrease [11] - The focus for the remainder of fiscal 2025 includes launching the G7 15 Day CGM, scaling Stelo, and enhancing access for type 2 diabetes patients [12]

Financial Performance Highlights - Dexcom reported revenue of $1.157 billion in Q2 2025, with 15% organic revenue growth compared to Q2 2024[12] - The company generated over 300 bps of operating expense leverage compared to Q2 2024[12] - Non-GAAP Gross Profit was $695.9 million for the three months ended June 30, 2025[31], compared to $638.1 million for the three months ended June 30, 2024[31] - Adjusted EBITDA for the three months ended June 30, 2025, was $327.6 million, compared to $283.9 million for the three months ended June 30, 2024[31] Revenue Breakdown and Growth - Sensor & Other revenue reached $1.1178 billion in Q2 2025[38] - Hardware Revenue was $39.3 million in Q2 2025[38] - US Revenue in Q2 2025 was $841.0 million, representing a 15% year-over-year growth[40] - International (INT'L) Revenue in Q2 2025 was $316.1 million, a 16% year-over-year increase[40] 2025 Guidance - Dexcom updated its 2025 annual revenue guidance to $4.600-4.625 billion[25] - The company anticipates a Non-GAAP Operating Margin of approximately 21% and an Adjusted EBITDA Margin of around 30% for 2025[25] Strategic Highlights - Dexcom received FDA clearance for Dexcom G7 15 day[12] - Dexcom launched the AI Smart Food Logging feature[12]

Core Insights - DexCom, Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of 32 cents, missing the Zacks Consensus Estimate of 33 cents by 3% and matching the prior-year quarter's EPS [1] - Total revenues grew 12% year over year to $1.04 billion, beating the Zacks Consensus Estimate by 2%, driven by strong category demand despite short-term supply challenges [1][10] Revenue Details - Sensor and other revenues, which account for 96% of total revenues, increased 17% year over year to $997.2 million, while hardware revenues decreased 42% to $38.8 million [3] - U.S. revenues, representing 72% of total revenues, rose 15% year over year to $750.5 million, while international revenues improved 7% to $285.5 million [4] Margin Analysis - Adjusted gross profit totaled $596.2 million, up 4.8% from the prior-year quarter, with an adjusted gross margin of 57.5%, down 420 basis points year over year [5] - Adjusted operating income was $143.1 million, reflecting a 2.1% increase from the prior-year period, with an adjusted operating margin of 13.8%, down 140 basis points year over year [7] Financial Position - DexCom ended the first quarter with cash, cash equivalents, and marketable securities worth $2.7 billion, an increase from $2.58 billion in the previous quarter, and total assets amounted to $6.75 billion [8] 2025 Guidance - The company reiterated its 2025 revenue outlook of $4.6 billion, implying 14% year-over-year growth, and expects an adjusted gross margin of approximately 62% [9] Operational Highlights - DexCom's operational performance was driven by robust category demand and significant access wins, with record acceleration in demand from new customers attributed to expanded commercial reach [10] - Key product innovations included the launch of Stelo, the first over-the-counter CGM, and several software updates enhancing customer experience [11] Market Access and Regulatory Developments - The company secured coverage with two of the three largest pharmacy benefit managers for all diabetes patients, leading to a significant increase in new starts from the type 2 non-insulin population [12] - DexCom received FDA clearance for its 15-Day Dexcom G7 System, expected to launch in the second half of 2025 [13] International Performance - Internationally, DexCom experienced growth in key markets like Japan and France, despite facing short-term supply challenges [14]

Dexcom Dexcom earnings Q1 2025 niabetes Nasdag Safe harbor statement Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "targets," "guidance," "expects," "intends, ""may," "plans," "potential," "predicts, " "prospects, " "should," "will," "would" or similar expressions and the negatives of those terms, although not all forward-looking statements contain these identifying words. Forwa ...

Raymond James Institutional Investors Conference 2 Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "targets," "guidance," "expects," "intends," "may," "plans," "potential," "predicts," "prospects," "projects," "should," "will," "would" or similar expressions and the negatives of those terms, although not all forward-looking statements contain these identifying words. Forward-looki ...